Procarbazine · Matulane

What is Procarbazine?

Procarbazine is a methylhydrazine derivative antineoplastic agent used in combination chemotherapy. After metabolic activation, it inhibits methionine trans-methylation into transfer RNA, preventing protein synthesis and consequently DNA and RNA synthesis. It may also generate cytotoxic free radicals that damage DNA through alkylation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Matulane

Drug type

Small molecule

Mechanism

Cytotoxic

Pathways

DNA synthesis, RNA synthesis, protein synthesis

Therapy area

Oncology

Developer

Leadiant Biosci Inc

In trials of

BMY

FDA status

Approved as Matulane (July 22, 1969), NDA016785 · FDA label

UNII

35S93Y190K

✅ FDA-approved uses

• Stage III and IV Hodgkin's disease

From the indications section of the FDA label (version of Sep 16, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lymphoma

Sources

• FDA label Matulane (2024-09-16), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT07015242

Updated Oct 3, 2026.